Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$11.39 USD
-0.46 (-3.88%)
Updated May 24, 2024 04:00 PM ET
After-Market: $11.40 +0.01 (0.09%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DVAX 11.39 -0.46(-3.88%)
Will DVAX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DVAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DVAX
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
DVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results
Other News for DVAX
Unveiling Dynavax Technologies (DVAX)'s Value: Is It Really Priced Right? A Comprehensive Guide
Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Dynavax (DVAX) and Natera (NTRA)
Wall Street Analysts Are Bullish on Top Healthcare Picks
Hold Rating on Dynavax Amidst FDA Setback and Long-term Profitability Focus
Analysts’ Top Healthcare Picks: aTyr Pharma (LIFE), Dynavax (DVAX)